ATR and ovarian carcinoma: Altogether, the results demonstrated that the combination of a platinum-based chemotherapy agent with an ATR inhibitor improves therapeutic outcomes in an ovarian cancer model, and could represent a potential novel strategy for overcoming the clinical recurrence of ovarian cancer (Fig. 8).